- Home
- SLSR vs RLAY Comparison
SLSR vs RLAY Comparison
Compare SLSR & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSR
- RLAY
- Stock Information
- Founded
- SLSR 2018
- RLAY 2015
- Country
- SLSR Switzerland
- RLAY United States
- Employees
- SLSR N/A
- RLAY N/A
- Industry
- SLSR
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLSR
- RLAY Health Care
- Exchange
- SLSR NYSE
- RLAY Nasdaq
- Market Cap
- SLSR 539.0M
- RLAY 610.3M
- IPO Year
- SLSR N/A
- RLAY 2020
- Fundamental
- Price
- SLSR $4.82
- RLAY $3.70
- Analyst Decision
- SLSR Buy
- RLAY Strong Buy
- Analyst Count
- SLSR 2
- RLAY 11
- Target Price
- SLSR $11.00
- RLAY $18.40
- AVG Volume (30 Days)
- SLSR 62.0K
- RLAY 2.5M
- Earning Date
- SLSR 08-08-2025
- RLAY 08-05-2025
- Dividend Yield
- SLSR N/A
- RLAY N/A
- EPS Growth
- SLSR N/A
- RLAY N/A
- EPS
- SLSR N/A
- RLAY N/A
- Revenue
- SLSR N/A
- RLAY $7,679,000.00
- Revenue This Year
- SLSR N/A
- RLAY $17.59
- Revenue Next Year
- SLSR N/A
- RLAY N/A
- P/E Ratio
- SLSR N/A
- RLAY N/A
- Revenue Growth
- SLSR N/A
- RLAY N/A
- 52 Week Low
- SLSR $1.90
- RLAY $1.78
- 52 Week High
- SLSR $5.88
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- SLSR 52.70
- RLAY 57.08
- Support Level
- SLSR $4.70
- RLAY $3.54
- Resistance Level
- SLSR $5.31
- RLAY $3.88
- Average True Range (ATR)
- SLSR 0.21
- RLAY 0.19
- MACD
- SLSR -0.06
- RLAY -0.01
- Stochastic Oscillator
- SLSR 36.02
- RLAY 53.00
About SLSR SOLARIS RESOURCES INC
Solaris Resources Inc is advancing a portfolio of copper and gold assets in the Americas, which includes a high-grade resource with expansion and additional discovery potential at the Warintza copper and gold project in Ecuador; discovery potential on the grass-roots Tamarugo project in Chile and Capricho and Paco Orco projects in Peru, and the La Verde joint venture project.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).